- Home
- TERN vs TRVI Comparison
TERN vs TRVI Comparison
Compare TERN & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TERN
- TRVI
- Stock Information
- Founded
- TERN 2017
- TRVI 2011
- Country
- TERN United States
- TRVI United States
- Employees
- TERN N/A
- TRVI N/A
- Industry
- TERN Biotechnology: Pharmaceutical Preparations
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- TERN Health Care
- TRVI Health Care
- Exchange
- TERN Nasdaq
- TRVI Nasdaq
- Market Cap
- TERN 634.5M
- TRVI 725.7M
- IPO Year
- TERN 2021
- TRVI 2019
- Fundamental
- Price
- TERN $7.22
- TRVI $7.01
- Analyst Decision
- TERN Buy
- TRVI Strong Buy
- Analyst Count
- TERN 6
- TRVI 10
- Target Price
- TERN $13.99
- TRVI $19.35
- AVG Volume (30 Days)
- TERN 1.2M
- TRVI 2.0M
- Earning Date
- TERN 08-05-2025
- TRVI 11-05-2025
- Dividend Yield
- TERN N/A
- TRVI N/A
- EPS Growth
- TERN N/A
- TRVI N/A
- EPS
- TERN N/A
- TRVI N/A
- Revenue
- TERN N/A
- TRVI N/A
- Revenue This Year
- TERN N/A
- TRVI N/A
- Revenue Next Year
- TERN N/A
- TRVI N/A
- P/E Ratio
- TERN N/A
- TRVI N/A
- Revenue Growth
- TERN N/A
- TRVI N/A
- 52 Week Low
- TERN $1.87
- TRVI $2.36
- 52 Week High
- TERN $11.40
- TRVI $8.78
- Technical
- Relative Strength Index (RSI)
- TERN 59.36
- TRVI 44.05
- Support Level
- TERN $6.78
- TRVI $7.09
- Resistance Level
- TERN $7.78
- TRVI $8.78
- Average True Range (ATR)
- TERN 0.49
- TRVI 0.43
- MACD
- TERN -0.02
- TRVI -0.07
- Stochastic Oscillator
- TERN 63.82
- TRVI 4.32
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.